Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James W Tetrud

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
CNS Spectrums|April 12, 2007
Balancing short-term symptom control and long-term functional outcomes in patients with Parkinson's diseaseJames W Tetrud
Neurology|October 13, 2004
A novel formulation of selegiline for the treatment of Parkinson's diseaseJames W Tetrud, William C Koller
Neurophysiologie Clinique = Clinical Neurophysiology|May 31, 2002
Voluntarily simulated tremor in normal subjectsPierre R Burkhard, J William Langston, James W Tetrud
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|November 18, 2005
Neurodegenerative disorders mimicking progressive supranuclear palsy: a report of three casesMarjorie A Murphy, Joseph H Friedman, James W Tetrud, et al.
Journal of Parkinson'S Disease|August 13, 2013
Mitochondrial dysfunction in skin fibroblasts from a Parkinson's disease patient with an alpha-synuclein triplicationSally K Mak, Deepika Tewari, James W Tetrud, et al.
The Lancet. Neurology|March 20, 2018
MPTP-induced parkinsonism: an historical case seriesJorik Nonnekes, Bart Post, James W Tetrud, et al.
Frontiers in Bioscience : a Journal and Virtual Library|April 18, 2003
Rest tremor in rhesus monkeys with MPTP-induced parkinsonismMarina E Emborg, James W Tetrud, Jeff Moirano, et al.
Annals of Neurology|February 29, 2008
Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005)Peter A LeWitt, M Guttman, James W Tetrud, et al.
Parkinsonism & Related Disorders|November 19, 2010
Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's diseaseWilliam G Ondo, Christine Hunter, Stuart H Isaacson, et al.
Journal of Parkinson'S Disease|February 27, 2018
LRRK2 p.Ile1371Val Mutation in a Case with Neuropathologically Confirmed Multi-System AtrophyKelsey Lee, Khanh-Dung Nguyen, Chao Sun, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
CNS Spectrums|April 12, 2007
Balancing short-term symptom control and long-term functional outcomes in patients with Parkinson's diseaseJames W Tetrud
Neurology|October 13, 2004
A novel formulation of selegiline for the treatment of Parkinson's diseaseJames W Tetrud, William C Koller
Neurophysiologie Clinique = Clinical Neurophysiology|May 31, 2002
Voluntarily simulated tremor in normal subjectsPierre R Burkhard, J William Langston, James W Tetrud
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|November 18, 2005
Neurodegenerative disorders mimicking progressive supranuclear palsy: a report of three casesMarjorie A Murphy, Joseph H Friedman, James W Tetrud, et al.
Journal of Parkinson'S Disease|August 13, 2013
Mitochondrial dysfunction in skin fibroblasts from a Parkinson's disease patient with an alpha-synuclein triplicationSally K Mak, Deepika Tewari, James W Tetrud, et al.
The Lancet. Neurology|March 20, 2018
MPTP-induced parkinsonism: an historical case seriesJorik Nonnekes, Bart Post, James W Tetrud, et al.
Frontiers in Bioscience : a Journal and Virtual Library|April 18, 2003
Rest tremor in rhesus monkeys with MPTP-induced parkinsonismMarina E Emborg, James W Tetrud, Jeff Moirano, et al.
Annals of Neurology|February 29, 2008
Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005)Peter A LeWitt, M Guttman, James W Tetrud, et al.
Parkinsonism & Related Disorders|November 19, 2010
Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's diseaseWilliam G Ondo, Christine Hunter, Stuart H Isaacson, et al.
Journal of Parkinson'S Disease|February 27, 2018
LRRK2 p.Ile1371Val Mutation in a Case with Neuropathologically Confirmed Multi-System AtrophyKelsey Lee, Khanh-Dung Nguyen, Chao Sun, et al.
Pageof 2